Enanta Pharmaceuticals, Inc. (ENTA)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Enanta Pharmaceuticals, Inc. (ENTA) is down 15.2% since the beginning of the year. At $13 per share, ENTA is trading 22.0% below its 52-week high of $17. Investors who bought $1,000 worth of ENTA shares 5 years ago would now be looking at an investment worth $280.

Enanta Pharmaceuticals, Inc. (ENTA) has returned -15.22% so far this year and 86.21% over the past 12 months. Over the last ten years, ENTA has returned -4.99% per year, falling short of the S&P 500 Index benchmark, which averaged 13.88% annually.

Based on dividend-adjusted daily data since Mar 21, 2013, ENTA's average daily return is +0.07%, while the average monthly return is +1.20%. At this rate, an investment would double in approximately 4.8 years.

Historically, 52% of months were positive and 48% were negative. The best month was Feb 2025 with a return of +52.3%, while the worst month was May 2022 at -38.0%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 9 months.

On a daily basis, ENTA closed higher 50% of trading days. The best single day was Sep 29, 2025 with a return of +91.9%, while the worst single day was Oct 22, 2015 at -40.6%.

Enanta Pharmaceuticals, Inc. has an annualized alpha of 4.12%, beta of 0.96, and R2 of 0.07 versus S&P 500 Index. Calculated based on daily prices since March 21, 2013.

• This stock participated in 107.63% of S&P 500 Index downside but only 52.64% of its upside - more exposed to losses than it benefited from rallies.
• R2 of 0.07 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

ENTA ranks 77 for risk / return — better than 77% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Enanta Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Enanta Pharmaceuticals, Inc. was 96.63%, occurring on Apr 10, 2025. The portfolio has not yet recovered.

The current Enanta Pharmaceuticals, Inc. drawdown is 89.42%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Enanta Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Enanta Pharmaceuticals, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.